Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Distribution

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Revenue projections:

Revenue projections for COR
Revenue projections for COR

Cencora, Inc.'s revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 0.916000
forwardPE 15.721397
debtToEquity 472.584000
earningsGrowth 0.148000
revenueGrowth 0.055000
grossMargins 0.036130
operatingMargins 0.011810
trailingEps 8.320000
forwardEps 19.591770

Cencora, Inc.'s Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
COR's high debt-to-equity ratio indicates the company is using significant leverage, relying more on debt to finance its operations. This can lead to higher risk, especially if profitability falters or economic conditions worsen.
COR's forward EPS exceeding its trailing EPS reflects expectations of increased profitability for the current year. This suggests that the company is projected to achieve higher earnings than in the previous financial year, signaling positive growth and improved financial health.

Price projections:

Price projections for COR
Price projections for COR

COR's present price, in comparison to its projections, indicates no evident risks or opportunities. This balanced scenario suggests a steady environment, where investors might choose to wait for more definitive indicators before altering their strategies.

Insider Transactions:

Insider Transactions for COR
Insider Transactions for COR


There were 30 transactions selling Cencora, Inc. stock, with prevailing market price of 299.00633290608727.COR saw 1 buy transactions, with market price of 260.6700134277344.The ongoing selling activity at COR's current price levels suggests a potential risk of further declines. If more investors continue to sell, this trend could lead to continued downward pressure on the stock's price.

Recommendation changes over time:

Recommendations trend for COR
Recommendations trend for COR


Analysts have shown a buy bias for Cencora, Inc., marking it as a favorable investment option. This could inspire investors to see Cencora, Inc. as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.